 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Arcellx, Inc. (ACLX), a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. 
The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs.
Shares have formed a bullish "flag" on the news that the company has formed an alliance with Gilead. Gilead’s (GILD) wholly owned subsidiary Kite announced a global strategic collaboration with Arcellx to co-develop and co-commercialize the ACLX’s lead late-stage product candidate, CART-ddBCMA.
CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified to target multiple myeloma. The candidate is currently in phase II. The deal involves an upfront cash payment of $225 million to Arcellx and a $100 million equity investment from Gilead.
Higher share prices are expected.
Entry Point: $33.50
Stop Loss: $31.50
Trading Range: $6.03 - $34.68
Target Price: $37.00
